Operating

Change in AR

Pfizer Change in AR remained flat by 0.0% to $65.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 141.3%, from $27.25M to $65.75M. Over 4 years (FY 2021 to FY 2025), Change in AR shows a downward trend with a -48.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025Feb 26, 2026

How to read this metric

A decrease is generally positive as it indicates faster collection of cash from customers.

Detailed definition

This measures the change in the amount of money owed to the company by customers for goods or services delivered on cred...

Peer comparison

Standard metric for all companies; peers in medical devices monitor this closely to manage working capital cycles.

Metric ID: change_in_accounts_receivable

Historical Data

5 years
 FY'21FY'22FY'23FY'24FY'25
Value$3.81B-$261.00M-$347.00M$109.00M$263.00M
YoY Change-106.8%-33.0%+131.4%+141.3%
Range-$347.00M$3.81B
CAGR-48.7%
Avg YoY Growth+33.2%
Median YoY Growth+49.2%
Current Streak2 years growth

Frequently Asked Questions

What is Pfizer's change in ar?
Pfizer (PFE) reported change in ar of $65.75M in Q4 2025.
How has Pfizer's change in ar changed year-over-year?
Pfizer's change in ar increased by 141.3% year-over-year, from $27.25M to $65.75M.
What is the long-term trend for Pfizer's change in ar?
Over 4 years (2021 to 2025), Pfizer's change in ar has grown at a -48.7% compound annual growth rate (CAGR), from $3.81B to $263.00M.
What does change in ar mean?
The change in money owed to the company by customers for past sales.